Jekely G. The human genome sequence. A triumph of chemistry: If the history of molecular biology is written in the future, the first chapter should be devoted to the chemists who did the ground work. EMBO Rep. 2002;3:594-595.
Marian AJ. Molecular genetic studies of complex phenotypes. Transl Res. 2012;159:64-79.
Auton A, Brooks LD, Durbin RM, et al. A global reference for human genetic variation. Nature. 2015;526:68-74.
Wang Z, Liu X, Yang BZ, et al. The role and challenges of exome sequencing in studies of human diseases. Front Genet. 2013;4:160.
Thomas PD, Kejariwal A. Coding single-nucleotide polymorphisms associated with complex vs. Mendelian disease: Evolutionary evidence for differences in molecular effects. Proc Natl Acad Sci USA. 2004;101:15398-15403.
Chial, H. Rare genetic disorders: learning about genetic disease through gene mapping, SNPs, and microarray data. Nature Education. 2008;1:192.
Camp KM, Trujillo EB. Position of the Academy of Nutrition and Dietetics: nutritional genomics. J Acad Nutr Diet. 2014;114:299-312.
Freeman JL, Perry GH, Feuk L, et al. Copy number variation: new insights in genome diversity. Genome Res. 2006;16:949-961.
Almal SH, Padh H. Implications of gene copy-number variation in health and diseases. J Hum Genet. 2012;57:6-13.
McGovern DP, Kugathasan S, Cho JH. Genetics of inflammatory bowel diseases. Gastroenterology. 2015;149:1163-1176.
Federal Trade Commission. Direct-to-Consumer Genetic Tests. https://www.consumer.ftc.gov/articles/0166-direct-consumer-genetic-tests. Published February 2018. Accessed August 20, 2018.
Phillips AM. 'Only a click away - DTC genetics for ancestry, health, love...and more: A view of the business and regulatory landscape'. Appl Transl Genom. 2016;8:16-22.
National Institutes of Health. What kinds of direct-to-consumer genetic tests are available? https://ghr.nlm.nih.gov/primer/dtcgenetictesting/dtctesttypes. Published September 2018. Accessed September 10, 2018.
US Food and Drug Administration. (April 2017.) FDA allows marketing of first direct-to-consumer tests that provide genetic risk information for certain conditions. https://www.fda.gov/newsevents/newsroom/pressannouncements/ucm551185.htm. Accessed August 20, 2018.
US Food and Drug Administration. (March 2018.) FDA authorizes, with special controls, direct-to-consumer test that reports three mutations in the BRCA breast cancer genes. https://www.fda.gov/newsevents/newsroom/pressannouncements/ucm599560.htm. Accessed August 20, 2018.
McCarty CA, Fuchs MJ, Lamb A, et al. How do patients respond to genetic testing for age-related macular degeneration? Optom Vis Sci. 2018;95:166-170.
Centers for Disease Control and Prevention website. Tier 1 Genomics Applications and their Importance to Public Health. https://www.cdc.gov/genomics/implementation/toolkit/tier1.htm. Published March 2014. Accessed August 28, 2018.
European Society for Medical Oncology website. FDA Permits Marketing of First Direct-to-Consumer Genetic Carrier Test for Bloom Syndrome. https://www.esmo.org/Oncology-News/FDA-Permits-Marketing-of-First-Direct-to-Consumer-Genetic-Carrier-Test-for-Bloom-Syndrome. Published February 2015. Accessed August 20, 2018.
Tandy-Connor S, Guiltinan J, Krempely K, et al. False-positive results released by direct-to-consumer genetic tests highlight the importance of clinical confirmation testing for appropriate patient care. Genet Med. 2018. doi: 10.1038/gim.2018.38. [Epub ahead of print]
Doble B, Schofield DJ, Roscioli T, et al. Prioritising the application of genomic medicine. NPJ Genom Med. 2017;2:35.
National Institutes of Health. What are the benefits and risks of direct-to-consumer genetic testing? https://ghr.nlm.nih.gov/primer/dtcgenetictesting/dtcrisksbenefits. Published August 2018. Accessed August 20, 2018.
Hamilton JG, Lobel M, Moyer A. Emotional distress following genetic testing for hereditary breast and ovarian cancer: a meta-analytic review. Health Psychol. 2009;28:510-508.
Kurian AW, Ford JM. Multigene panel testing in oncology practice: how should we respond? JAMA Oncol. 2015;1:277-278.
Hoskovec JM, Bennett RL, Carey ME, et al. Projecting the supply and demand for certified genetic counselors: a workforce study. J Genet Couns. 2018;27:16-20.
American Board of Medical Specialties (ABMS) Board Certification Report. https://www.abms.org/media/139572/abms_board_certification_report_2016-17.pdf. Published 2017. Accessed August 28, 2018
Agency for Healthcare Research and Quality. The Number of Practicing Primary Care Physicians in the United States. https://www.ahrq.gov/research/findings/factsheets/primary/pcwork1/index.html. Published October 2011. Accessed August 20, 2018
Genetic Counselor Workforce Working Group. Strategic Plan 2017-2019. https://www.nsgc.org/d/do/7603. Published June 2017. Accessed August 20, 2018
Ormond KE, Laurino MY, Barlow-Stewart K, et al. Genetic counseling globally: where are we now? Am J Med Genet. 2018;178:98-107.
Puryear L, Downs N, Nevedal A, et al. Patient and provider perspectives on the development of personalized medicine: a mixed-methods approach. J Community Genet. 2018;9:283-291.
David SP, Palaniappan L. Clinical and personal utility of genetic risk testing. Am Fam Physician. 2018;97:600-602.
Carere DA, VanderWeele TJ, Vassy JL, et al. Prescription medication changes following direct-to-consumer personal genomic testing: findings from the Impact of Personal Genomics (PGen) Study. Genet Med. 2017;19:537-545.
US Preventive Services Task Force. Final Recommendation Statement: BRCA-Related Cancer: Risk Assessment, Genetic Counseling, and Genetic Testing. https://www.uspreventiveservicestaskforce.org/Page/Document/RecommendationStatementFinal/brca-related-cancer-risk-assessment-genetic-counseling-and-genetic-testing. Published December 2013. Accessed August 28, 2018.
Ashton-Prolla P, Giacomazzi J, Schmidt AV, et al. Development and validation of a simple questionnaire for the identification of hereditary breast cancer in primary care. BMC Cancer. 2009;9:283.
Bloss CS, Schork NJ, Topol EJ. Effect of direct-to-consumer genomewide profiling to assess disease risk. N Engl J Med. 2011;364:524-534.
Mavroidopoulou V, Xera E, Mollaki V. Awareness, attitudes and perspectives of direct-to-consumer genetic testing in Greece: a survey of potential consumers. J Hum Genet. 2015;60:515-523.
Schaper M, Wöhlke S, Schicktanz S. "I would rather have it done by a doctor"-laypeople's perceptions of direct-to-consumer genetic testing (DTC GT) and its ethical implications. Med Health Care Philos. 2018. doi: 10.1007/s11019-018-9837-y. [Epub ahead of print]

CME / ABIM MOC

The DTC Genetics Talk Show: Finding the Advantage for Patients

Authors: Charles P. Vega, MD; Latha Palaniappan, MD; Jason L. Vassy, MD, MPH
CME / ABIM MOC Released: 11/19/2018
THIS ACTIVITY HAS EXPIRED FOR CREDIT
Valid for credit through: 11/19/2019, 11:59 PM EST

Target Audience and Goal Statement

This activity is intended for primary care physicians, pediatricians, geneticists, genetic counselors, and other healthcare professionals who encounter patients with DTC genetic testing results

The goal of this activity is to provide education on genetic literacy and interpretation of direct-to-consumer (DTC) genetic testing in patients, including assessment, management, and follow-up based on DTC genetic screening results.

Upon completion of this activity, participants will:

Have increased knowledge regarding the
- DTC genetic tests that are currently available
- Use of DTC genetic testing in patients
Have greater competence related to
- Recommending appropriate follow-up, including assessment and management and/or referral based on DTC genetic screening test results
Demonstrate greater confidence in their ability to
- Communicate with patients and answer questions regarding DTC genetic testing

Chair

Charles P. Vega, MD

Clinical Professor, Health Sciences
Department of Family Medicine
University of California, Irvine School of Medicine

Disclosures

Disclosure: Charles P. Vega, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Shire Pharmaceuticals; Sunovion Pharmaceuticals Inc.
Served as a speaker or a member of a speakers bureau for: Shire Pharmaceuticals

Dr Vega does not intend to discuss off-label uses of drugs, mechanical devices, biologics, or diagnostics approved by the FDA for use in the United States.

Dr Vega does not intend to discuss investigational drugs, mechanical devices, biologics, or diagnostics not approved by the FDA for use in the United States.

Faculty

Latha Palaniappan, MD

Professor of Medicine
Stanford University School of Medicine
Stanford, California

Disclosures

Disclosure: Latha Palaniappan, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: 23andMe
Served as a speaker or a member of a speakers bureau for: Pfizer Inc.

Dr Palaniappan does not intend to discuss off-label uses of drugs, mechanical devices, biologics, or diagnostics approved by the FDA for use in the United States.

Dr Palaniappan does not intend to discuss investigational drugs, mechanical devices, biologics, or diagnostics not approved by the FDA for use in the United States.

Jason L. Vassy, MD, MPH

Assistant Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Disclosures

Disclosure: Jason L. Vassy, MD, MPH, has disclosed no relevant financial relationships.

Dr Vassy does not intend to discuss off-label uses of drugs, mechanical devices, biologics, or diagnostics approved by the FDA for use in the United States.

Dr Vassy does not intend to discuss investigational drugs, mechanical devices, biologics, or diagnostics not approved by the FDA for use in the United States.

Genetic Consultant

Michael J. Dougherty, PhD

Disclosures

Disclosure: Michael J. Dougherty, PhD, has disclosed no relevant financial relationships.

Patients

Sarina Escalante

Disclosures

Disclosure: Sarina Escalante has disclosed no relevant financial relationships.

Lindsey Schoolcraft

Disclosures

Disclosure: Lindsey Schoolcraft has disclosed no relevant financial relationships

Editor

Pakinam Aboulsaoud, PharmD

Scientific Director, Medscape, LLC

Disclosures

Disclosure: Pakinam Aboulsaoud, PharmD, has disclosed no relevant financial relationships.

CME Reviewer

Amy Bernard, MS, BSN, RN-BC, CHCP

Lead Nurse Planner, Medscape, LLC

Disclosures

Disclosure: Amy Bernard, MS, BSN, RN-BC, CHCP, has disclosed no relevant financial relationships.

Peer Reviewer

Marta Sabbadini, PhD

Disclosure: Marta Sabbadini, PhD, has disclosed no relevant financial relationships.

Accreditation Statements

In support of improving patient care, Medscape, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

For Physicians

Medscape, LLC designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

This Enduring Material activity, The DTC Genetics Talk Show: Finding the Advantage for Patients, has been reviewed and is acceptable for up to 1.00 Prescribed credit(s) by the American Academy of Family Physicians. AAFP certification begins 11/19/2018. Term of approval is for one year from this date. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Medscape, LLC staff have disclosed that they have no relevant financial relationships.

Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]

Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 70% on the post-test.

Follow these steps to earn CME/CE credit*:

Read the target audience, learning objectives, and author disclosures.
Study the educational content online or printed out.
Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

From Medscape Education Family Medicine

CME / ABIM MOC

The DTC Genetics Talk Show: Finding the Advantage for Patients

Authors: Charles P. Vega, MD; Latha Palaniappan, MD; Jason L. Vassy, MD, MPHFaculty and Disclosures

THIS ACTIVITY HAS EXPIRED FOR CREDIT

CME / ABIM MOC Released: 11/19/2018

Valid for credit through: 11/19/2019, 11:59 PM EST

processing....

Educational Impact Challenge

Before you begin this activity, please assess your clinical knowledge by completing this brief survey. Answering these questions again after the activity will allow you to see what you learned and to compare your answers with those of your peers.

Page 1 of 4

CME / ABIM MOC Information Download Slides

Print
Like Tweet

Disclaimer

The educational activity presented above may involve simulated case-based scenarios. The patients depicted in these scenarios are fictitious and no association with any actual patient is intended or should be inferred.

The material presented here does not necessarily reflect the views of Medscape, LLC, or companies that support educational programming on medscape.org. These materials may discuss therapeutic products that have not been approved by the US Food and Drug Administration and off-label uses of approved products. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity.

References

Faculty and Disclosures

Chair

Charles P. Vega, MD

Faculty

Latha Palaniappan, MD

Jason L. Vassy, MD, MPH

Genetic Consultant

Michael J. Dougherty, PhD

Patients

Sarina Escalante

Lindsey Schoolcraft

Editor

Pakinam Aboulsaoud, PharmD

CME Reviewer

Amy Bernard, MS, BSN, RN-BC, CHCP

CME / ABIM MOC

The DTC Genetics Talk Show: Finding the Advantage for Patients

Target Audience and Goal Statement

Chair

Charles P. Vega, MD

Faculty

Latha Palaniappan, MD

Jason L. Vassy, MD, MPH

Genetic Consultant

Michael J. Dougherty, PhD

Patients

Sarina Escalante

Lindsey Schoolcraft

Editor

Pakinam Aboulsaoud, PharmD

CME Reviewer

Amy Bernard, MS, BSN, RN-BC, CHCP

Accreditation Statements

For Physicians

Instructions for Participation and Credit

The DTC Genetics Talk Show: Finding the Advantage for Patients

Educational Impact Challenge